Details

Autor(en) / Beteiligte

• Yu, Szu-Hsien
• Wang, Tong-Hong
• Au, Lo-Chun

Titel

Specific repression of mutant K-RAS by 10–23 DNAzyme: Sensitizing cancer cell to anti-cancer therapies

Ist Teil von

• Biochemical and biophysical research communications, 2009-01, Vol.378 (2), p.230-234

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2009

Quelle

ScienceDirect

Beschreibungen/Notizen

• Point mutations of the Ras family are frequently found in human cancers at a prevalence rate of 30%. The most common mutation K-Ras(G12V), required for tumor proliferation, survival, and metastasis due to its constitutively active GTPase activity, has provided an ideal target for cancer therapy. 10–23 DNAzyme, an oligodeoxyribonucleotide-based ribonuclease consisting of a 15-nucleotide catalytical domain flanked by two target-specific complementary arms, has been shown to effectively cleave the target mRNA at purine–pyrimidine dinucleotide. Taking advantage of this specific property, 10–23 DNAzyme was designed to cleave mRNA of K-Ras(G12V)( GGU → GUU) at the GU dinucleotide while left the wild-type (WT) K-Ras mRNA intact. The K-Ras(G12V)-specific 10–23 DNAzyme was able to reduce K-Ras(G12V) at both mRNA and protein levels in SW480 cell carrying homozygous K-Ras(G12V). No effect was observed on the WT K-Ras in HEK cells. Although K-Ras(G12V)-specific DNAzymes alone did not inhibit proliferation of SW480 or HEK cells, pre-treatment of this DNAzyme sensitized the K-Ras(G12V) mutant cells to anti-cancer agents such as doxorubicin and radiation. These results offer a potential of using allele-specific 10–23 DNAzyme in combination with other cancer therapies to achieve better effectiveness on cancer treatment.